Galmed Pharmaceuticals Ltd. Stock
Galmed Pharmaceuticals Ltd. Stock price
Key metrics
| Market capitalization | $3.64m |
| Enterprise Value | $-12.09m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 2.32 |
| P/B ratio (TTM) P/B ratio | 0.22 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-7.28m |
| Free Cash Flow (TTM) Free Cash Flow | $-5.22m |
| Cash position | $15.73m |
Is Galmed Pharmaceuticals Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
Galmed Pharmaceuticals Ltd. Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:
Analyst Opinions
1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:
Financial data from Galmed Pharmaceuticals Ltd.
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -7.21 -7.21 |
5%
5%
|
EBIT (Operating Income) EBIT | -7.28 -7.28 |
6%
6%
|
| Net Profit | -7.35 -7.35 |
16%
16%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Galmed Pharmaceuticals Ltd. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galmed Pharmaceuticals Ltd. Stock News
Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
| Head office | Israel |
| CEO | Allen Baharaff |
| Employees | 5 |
| Founded | 2000 |
| Website | www.galmedpharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
